|
1
|
Iwamoto Y: Diagnosis and treatment of
Ewing's sarcoma. Jpn J Clin Oncol. 37:79–89. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grier HE, Krailo MD, Tarbell NJ, Link MP,
Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers
PA, et al: Addition of ifosfamide and etoposide to standard
chemotherapy for Ewing's sarcoma and primitive neuroectodermal
tumor of bone. N Engl J Med. 348:694–701. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miser JS, Krailo MD, Tarbell NJ, Link MP,
Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers
PA, et al: Treatment of metastatic Ewing's sarcoma or primitive
neuroectodermal tumor of bone: Evaluation of combination ifosfamide
and etoposide - a Children's cancer group and pediatric oncology
group study. J Clin Oncol. 22:2873–2876. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Longtin R: Ewing sarcoma: A miracle drug
waiting to happen? J Natl Cancer Inst. 95:1574–1576. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
May WA, Grigoryan RS, Keshelava N, Cabral
DJ, Christensen LL, Jenabi J, Ji L, Triche TJ, Lawlor ER and
Reynolds CP: Characterization and drug resistance patterns of
Ewing's sarcoma family tumor cell lines. PLoS One. 8:e800602013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fodale V, Pierobon M, Liotta L and
Petricoin E: Mechanism of cell adaptation: When and how do cancer
cells develop chemoresistance? Cancer J. 17:89–95. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iida K, Fukushi J, Matsumoto Y, et al:
miR-125b develops chemo-resistance in Ewing sarcomaprimitive
neuroectodermal tumor. Cancer Cell Int. 13:212013. View Article : Google Scholar
|
|
8
|
Bardelli A and Jänne PA: The road to
resistance: EGFR mutation and cetuximab. Nat Med. 18:199–200. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yewale C, Baradia D, Vhora I, Patil S and
Misra A: Epidermal growth factor receptor targeting in cancer: A
review of trends and strategies. Biomaterials. 34:8690–8707. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Red Brewer M, Yun CH, Lai D, Lemmon MA,
Eck MJ and Pao W: Mechanism for activation of mutated epidermal
growth factor receptors in lung cancer. Proc Natl Acad Sci USA.
110:E3595–E3604. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Graham J, Muhsin M and Kirkpatrick P:
Cetuximab. Nat Rev Drug Discov. 3:549–550. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fantin VR, St-Pierre J and Leder P:
Attenuation of LDH-A expression uncovers a link between glycolysis,
mitochondrial physiology and tumor maintenance. Cancer Cell.
6:425–434. 2006. View Article : Google Scholar
|
|
13
|
Maftouh M, Avan A, Sciarrillo R, Granchi
C, Leon LG, Rani R, Funel N, Smid K, Honeywell R, Boggi U, et al:
Synergistic interaction of novel lactate dehydrogenase inhibitors
with gemcitabine against pancreatic cancer cells in hypoxia. Br J
Cancer. 110:172–182. 2014. View Article : Google Scholar :
|
|
14
|
Lu H, Li X, Luo Z, Liu J and Fan Z:
Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated
LDH-A. Mol Cancer Ther. 12:2187–2199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
16
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Henderson SR, Guiliano D, Presneau N,
McLean S, Frow R, Vujovic S, Anderson J, Sebire N, Whelan J,
Athanasou N, et al: A molecular map of mesenchymal tumors. Genome
Biol. 206:R762005. View Article : Google Scholar
|
|
18
|
Zhou M, Zhao Y, Ding Y, Liu H, Liu Z,
Fodstad O, Riker AI, Kamarajugadda S, Lu J, Owen LB, et al: Warburg
effect in chemosensitivity: Targeting lactate dehydrogenase-A
re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer.
9:332010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li X, Zhao H, Zhou X and Song L:
Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes
colon cancer cells to 5-fluorouracil. Mol Med Rep. 11:577–582.
2015.
|
